Overall (n = 400) | No change in therapy based on MRD (n = 333) | Change in therapy based on MRD (n = 67) | |
---|---|---|---|
Male (%) | 55 | 57 | 45 |
Mean age, years (sd) | 58.9 (0.4) | 59.2 (0.7) | 57.1 (1.3) |
Myeloma type, (%) | |||
IgG | 55 | 56 | 46 |
IgA | 19 | 19 | 20 |
Light chain only | 19 | 17 | 27 |
High risk cytogenetics*, (%) | 17 | 17 | 16 |
ISS, (%) | |||
I | 38 | 35 | 40 |
II | 26 | 28 | 38 |
III | 35 | 33 | 27 |
Hemoglobin, (g/dL) (sd) | 12.5 (0.7) | 12.6 (0.7) | 12.1 (1.2) |
High LDH levels, (%) | 20 | 20 | 21 |
Induction treatment, (%) | |||
CyBorD | 19 | 19 | 19 |
VRD/VTD | 45 | 49 | 40 |
Others | 36 | 32 | 41 |
ASCT, yes (%) | 78 | 78 | 81 |
Maintenance, yes (%) | 82 | 82 | 91 |